Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma

AV-GBM-1 - AiVita Biomedical

temozolomide - Generic mfg.

https://jitc.bmj.com//content/9/Suppl_2/A362

David Piccioni 1; David Piccioni 1; Daniela Bota 2; Renato LaRocca 3; Santosh Kesari 4; Jose Carillo 4; Xiao-Tang Kong 2; Christopher Duma 5; Mehrdad Abedi 6; Robert Aiken 7; Thomas Taylor 2; Candace Hsieh 8; Gabriel Nistor 8; Robert Dillman 8

Oct 1, 2021